Experimental drug tazemetostat offered to patients with rare, aggressive tumors

NCT ID NCT03874455

NO_LONGER_AVAILABLE Disease control Sponsor: Epizyme, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a formal clinical trial. The goal is to offer a potential option when no standard therapies remain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tazemetostat

What this could lead to

If it works, this could provide a treatment option for people with rare, aggressive tumors who have run out of standard therapies.

What could go wrong

This is an expanded access program, not a formal trial, so results are limited and may not prove effectiveness. Tazemetostat may cause side effects and not shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical teratoid rhabdoid tumor chondrosarcoma collecting duct carcinoma desmoplastic small round cell tumor epithelioid malignant peripheral nerve sheath tumor epithelioid sarcoma malignant mesothelioma malignant myoepithelioma Mesothelioma, Malignant nasal cavity and paranasal sinus carcinoma poorly differentiated chordoma renal cell carcinoma rhabdoid tumor rhabdoid tumor of the kidney sarcoma spindle cell sarcoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRT CHONDROSARCOMA DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) EPITHELIOID MALIGNANT PERIPHERAL NERVE SHEATH TUMOR EPITHELIOID SARCOMA (EX-US ONLY) INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS MALIGNANT MESOTHELIOMA MALIGNANT RHABDOID TUMOR MALIGNANT RHABDOID TUMOR OF KIDNEY MALIGNANT RHABDOID TUMOR OF OVARY MYOEPITHELIAL CARCINOMA MYXOID SPINDLE CELL SARCOMA POORLY DIFFERENTIATED CHORDOMA RENAL CELL CARCINOMA RENAL MEDULLARY CARCINOMA SINONASAL CARCINOMA SMALL CELL CARCINOMA OF THE OVARY HYPERCALCEMIC TYPE SPINDLE CELL SARCOMA SYNOVIAL SARCOMA THORACIC SARCOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.